OpenLB
Open Library of Bioscience
Advanced Search
Pharmaceuticals (Basel, Switzerland)
Jul 10, 2024;17 (7):

Indole Compounds in Oncology: Therapeutic Potential and Mechanistic Insights.

Sara M Hassan, Alyaa Farid, Siva S Panda, Mohamed S Bekheit, Holden Dinkins, Walid Fayad, Adel S Girgis
Author Information
  1. Sara M Hassan: Biotechnology Department, Faculty of Science, Cairo University, Giza 12613, Egypt. ORCID
  2. Alyaa Farid: Biotechnology Department, Faculty of Science, Cairo University, Giza 12613, Egypt. ORCID
  3. Siva S Panda: Department of Chemistry and Biochemistry, Augusta University, Augusta, GA 30912, USA. ORCID
  4. Mohamed S Bekheit: Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt.
  5. Holden Dinkins: Department of Chemistry and Biochemistry, Augusta University, Augusta, GA 30912, USA.
  6. Walid Fayad: Drug Bioassay-Cell Culture Laboratory, Pharmacognosy Department, National Research Centre, Dokki, Giza 12622, Egypt.
  7. Adel S Girgis: Department of Pesticide Chemistry, National Research Centre, Dokki, Giza 12622, Egypt. ORCID
PMID: 39065774 DOI: 10.3390/ph17070922

Abstract

Cancer remains a formidable global health challenge, with current treatment modalities such as chemotherapy, radiotherapy, surgery, and targeted therapy often hindered by low efficacy and adverse side effects. The indole scaffold, a prominent heterocyclic structure, has emerged as a promising candidate in the fight against cancer. This review consolidates recent advancements in developing natural and synthetic indolyl analogs, highlighting their antiproliferative activities against various cancer types over the past five years. These analogs are categorized based on their efficacy against common cancer types, supported by biochemical assays demonstrating their antiproliferative properties. In this review, emphasis is placed on elucidating the mechanisms of action of these compounds. Given the limitations of conventional cancer therapies, developing targeted therapeutics with enhanced selectivity and reduced side effects remains a critical focus in oncological research.

Keywords

antiproliferation cancer indole mode of action synthesis

References

Chem Biol Interact. 2023 Sep 25;383:110682 [PMID: 37648047]
Biomolecules. 2019 Aug 13;9(8): [PMID: 31412593]
Bioorg Chem. 2021 Feb;107:104626 [PMID: 33450545]
Molecules. 2020 Jan 14;25(2): [PMID: 31947550]
Eur J Med Chem. 2018 Feb 25;146:206-219 [PMID: 29407951]
Clin Cancer Res. 2017 Mar 1;23(5):1137-1148 [PMID: 27940520]
Org Biomol Chem. 2014 Oct 7;12(37):7238-49 [PMID: 25081868]
Molecules. 2023 Jan 07;28(2): [PMID: 36677676]
Eur J Med Chem. 2023 Dec 5;261:115858 [PMID: 37837671]
RSC Adv. 2019 Mar 28;9(17):9809-9819 [PMID: 35520746]
J Nat Prod. 2022 Apr 22;85(4):1067-1078 [PMID: 35213164]
ACS Omega. 2022 Sep 27;7(40):35743-35754 [PMID: 36249408]
Bioorg Chem. 2020 Jan;95:103519 [PMID: 31884140]
Eur J Med Chem. 2018 Jan 20;144:104-115 [PMID: 29268127]
Eur J Med Chem. 2020 May 15;194:112245 [PMID: 32220687]
Molecules. 2023 Sep 13;28(18): [PMID: 37764378]
Expert Opin Investig Drugs. 2017 Nov;26(11):1295-1305 [PMID: 28965421]
Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):189013 [PMID: 37918452]
Molecules. 2018 Sep 12;23(9): [PMID: 30213123]
Pharmazie. 1996 Aug;51(8):544-8 [PMID: 8794465]
BMC Cancer. 2020 Jul 7;20(1):629 [PMID: 32635894]
Chem Biol Interact. 2018 Jan 25;280:99-108 [PMID: 29225138]
Eur J Med Chem. 2019 Nov 1;181:111570 [PMID: 31408809]
Sci Rep. 2022 Aug 16;12(1):13880 [PMID: 35974029]
Eur J Med Chem. 2019 Mar 15;166:108-118 [PMID: 30685534]
Nat Prod Res. 2021 Jan;35(1):144-151 [PMID: 31135217]
Nat Rev Clin Oncol. 2021 Dec;18(12):773-791 [PMID: 34285417]
Cell Res. 2019 May;29(5):347-364 [PMID: 30948788]
Bioorg Chem. 2019 Apr;85:399-412 [PMID: 30665034]
Signal Transduct Target Ther. 2022 Aug 13;7(1):286 [PMID: 35963853]
Eur J Med Chem. 2021 Feb 5;211:112999 [PMID: 33189439]
JAMA Netw Open. 2021 Apr 1;4(4):e214708 [PMID: 33825840]
Arch Pharm (Weinheim). 2021 Feb;354(2):e2000266 [PMID: 32986279]
RSC Adv. 2018 Apr 17;8(26):14335-14346 [PMID: 35540737]
Nature. 2019 Nov;575(7782):299-309 [PMID: 31723286]
Molecules. 2022 Nov 28;27(23): [PMID: 36500375]
Eur J Med Chem. 2021 Jun 5;218:113400 [PMID: 33823394]
Fitoterapia. 2023 Mar;165:105430 [PMID: 36634875]
Arch Pharm (Weinheim). 2020 Nov;353(11):e2000131 [PMID: 32785974]
Int J Mol Sci. 2018 Oct 31;19(11): [PMID: 30384473]
3 Biotech. 2020 Apr;10(4):187 [PMID: 32257743]
Cell Death Dis. 2021 Oct 14;12(10):947 [PMID: 34650051]
Eur J Med Chem. 2018 Apr 25;150:9-29 [PMID: 29505935]
Biochemistry. 2016 May 31;55(21):3020-35 [PMID: 27110637]
Bioorg Chem. 2019 Nov;92:103188 [PMID: 31450167]
J Pharmacol Exp Ther. 2018 Mar;364(3):494-503 [PMID: 29263244]
Bioorg Med Chem. 2006 Dec 15;14(24):8488-94 [PMID: 16973365]
Nat Commun. 2020 Jun 26;11(1):3236 [PMID: 32591543]
Clin Exp Med. 2023 Jul;23(3):553-567 [PMID: 36109471]
RSC Adv. 2022 Oct 31;12(48):31102-31123 [PMID: 36349009]
Phytochemistry. 2021 Jun;186:112744 [PMID: 33780702]
J Hematol Oncol. 2022 Dec 8;15(1):174 [PMID: 36482419]
Pharmazie. 2020 Dec 1;75(12):642-645 [PMID: 33303057]
Bioorg Chem. 2024 Jan;142:106930 [PMID: 37890212]
Eur J Med Res. 2019 Jan 28;24(1):5 [PMID: 30686270]
Org Biomol Chem. 2015 Jun 21;13(23):6619-33 [PMID: 25988330]
Eur J Med Chem. 2023 Feb 15;248:115087 [PMID: 36610250]
Org Biomol Chem. 2015 Feb 14;13(6):1741-53 [PMID: 25502495]
Eur J Med Chem. 2024 Jan 5;263:115794 [PMID: 37984295]
Eur J Med Chem. 2024 Feb 5;265:116100 [PMID: 38171149]
J Nat Prod. 2021 Jul 23;84(7):1904-1914 [PMID: 34176266]
Mol Cancer Ther. 2017 Jul;16(7):1224-1235 [PMID: 28396364]
Cancers (Basel). 2023 Jan 18;15(3): [PMID: 36765543]
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49 [PMID: 38230766]
Bioorg Med Chem. 2022 Jan 1;53:116534 [PMID: 34864496]
Front Oncol. 2021 May 20;11:664853 [PMID: 34094958]
Eur J Med Chem. 2020 Jun 15;196:112293 [PMID: 32311607]
J Hematol Oncol. 2018 Sep 19;11(1):120 [PMID: 30231931]
J Hematol Oncol. 2022 Sep 14;15(1):133 [PMID: 36104717]
Eur J Med Chem. 2019 May 15;170:73-86 [PMID: 30878833]
Bioorg Chem. 2019 Apr;85:475-486 [PMID: 30776558]
AMB Express. 2020 Aug 18;10(1):148 [PMID: 32809085]
Bioorg Chem. 2022 Mar;120:105607 [PMID: 35033818]
Eur J Med Chem. 2018 Aug 5;156:722-737 [PMID: 30041136]
Pathol Res Pract. 2021 Aug;224:153437 [PMID: 34271345]
Bioorg Chem. 2024 Jan;142:106957 [PMID: 37939507]
Org Biomol Chem. 2019 Apr 17;17(16):3914-3920 [PMID: 30942251]
Drug Des Devel Ther. 2020 Feb 03;14:483-495 [PMID: 32099332]
Bioorg Chem. 2020 Dec;105:104440 [PMID: 33217633]
Eur J Med Chem. 2017 Jul 7;134:392-405 [PMID: 28433679]
Eur J Med Chem. 2019 Nov 15;182:111621 [PMID: 31442685]
Eur J Med Chem. 2018 Jul 15;155:13-23 [PMID: 29852328]
Int J Oncol. 2019 Jun;54(6):1995-2004 [PMID: 31081045]
Molecules. 2023 Feb 17;28(4): [PMID: 36838932]
Bioorg Chem. 2019 Mar;84:410-417 [PMID: 30554080]
Bioorg Chem. 2021 Sep;114:105117 [PMID: 34214752]
Comput Biol Chem. 2019 Jun;80:512-523 [PMID: 31185422]
CA Cancer J Clin. 2023 May-Jun;73(3):233-254 [PMID: 36856579]
Eur J Med Chem. 2018 May 25;152:283-297 [PMID: 29730191]
Bioorg Chem. 2021 Sep;114:105131 [PMID: 34243074]
Phytother Res. 2022 Mar;36(3):1353-1371 [PMID: 35112410]
Bioorg Chem. 2024 Jan;142:106970 [PMID: 37984101]
Bioorg Chem. 2018 Dec;81:1-20 [PMID: 30081353]
Phytother Res. 2019 May;33(5):1570-1578 [PMID: 30907037]
Anticancer Drugs. 2022 Apr 1;33(4):362-370 [PMID: 35266886]
CA Cancer J Clin. 2023 Jan;73(1):17-48 [PMID: 36633525]
Mar Drugs. 2021 Aug 27;19(9): [PMID: 34564151]
Eur J Med Chem. 2019 Mar 15;166:281-290 [PMID: 30731397]
J Med Chem. 2021 Oct 14;64(19):14702-14714 [PMID: 34528437]
Nat Prod Res. 2020 Aug;34(16):2283-2288 [PMID: 30580623]
J Enzyme Inhib Med Chem. 2018 Dec;33(1):309-318 [PMID: 29281924]
Eur J Med Chem. 2020 Aug 15;200:112359 [PMID: 32531682]
Eur J Med Chem. 2023 Apr 5;252:115292 [PMID: 36965227]
Eur J Med Chem. 2020 Aug 15;200:112459 [PMID: 32502865]
Med Clin North Am. 2022 May;106(3):411-422 [PMID: 35491062]
Bioorg Chem. 2024 Mar;144:107096 [PMID: 38290186]
Nat Prod Res. 2022 Mar;36(6):1454-1459 [PMID: 33678090]
Life Sci. 2019 Sep 1;232:116615 [PMID: 31260686]
Eur J Med Chem. 2019 Oct 15;180:562-612 [PMID: 31344615]
Front Oncol. 2022 Jun 23;12:891652 [PMID: 35814435]
Eur J Med Chem. 2022 Jan 5;227:113893 [PMID: 34656899]
Bioorg Chem. 2022 Feb;119:105557 [PMID: 34952242]
J Gene Med. 2023 Nov;25(11):e3550 [PMID: 37354071]
ACS Omega. 2022 Nov 10;7(46):42036-42043 [PMID: 36440122]
Bioorg Chem. 2021 Dec;117:105466 [PMID: 34775204]
Eur J Histochem. 2018 Apr 10;62(2):2881 [PMID: 29943949]
Eur J Med Chem. 2024 Feb 5;265:116061 [PMID: 38154256]
Cancer. 2021 Aug 15;127(16):3029-3030 [PMID: 34086348]
Hum Exp Toxicol. 2021 May;40(5):812-825 [PMID: 33118390]
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1563-1579 [PMID: 31575553]
Eur J Med Chem. 2019 Jan 15;162:525-533 [PMID: 30472600]
Eur J Med Chem. 2013 May;63:14-21 [PMID: 23454530]
Laeknabladid. 2014 Feb;100(2):75-82 [PMID: 24639430]
Org Lett. 2016 Aug 5;18(15):3534-7 [PMID: 27458880]
Drugs. 2018 Jul;78(10):1057-1062 [PMID: 29943374]
Bioorg Chem. 2019 Feb;82:423-430 [PMID: 30508794]
Mar Drugs. 2023 Mar 29;21(4): [PMID: 37103358]
Molecules. 2022 Sep 12;27(18): [PMID: 36144662]
RSC Adv. 2024 Feb 14;14(9):5690-5728 [PMID: 38362086]
Cancers (Basel). 2019 Jul 22;11(7): [PMID: 31336690]
ChemMedChem. 2021 Nov 19;16(22):3418-3427 [PMID: 34352160]
Eur J Med Chem. 2023 Oct 5;258:115563 [PMID: 37329713]
Eur J Med Chem. 2018 Sep 5;157:665-682 [PMID: 30125725]
Nat Rev Drug Discov. 2021 Mar;20(3):200-216 [PMID: 33510482]

Grants

  1. 13060103/the National Research Centre, Egypt
Journal Article Review

Word Cloud

Similar Articles

Cited By